Approval · Notice of Compliance 26998 · 2021
ABEVMY: Notice of Compliance 26998
Issued November 5, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26998
- Date
- November 5, 2021
- Company
- BGP Pharma ULCEtobicoke, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
- Canadian reference product
- AVASTIN
Products in this notice
Medicinal ingredients
- BEVACIZUMAB 100 MG per VIAL
- BEVACIZUMAB 400 MG per VIAL